These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 32549916)

  • 1. Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.
    Reddy V; Grogan D; Ahluwalia M; Salles ÉL; Ahluwalia P; Khodadadi H; Alverson K; Nguyen A; Raju SP; Gaur P; Braun M; Vale FL; Costigliola V; Dhandapani K; Baban B; Vaibhav K
    EPMA J; 2020 Jun; 11(2):217-250. PubMed ID: 32549916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid System: A Multi-Facet Therapeutic Target.
    Kaur R; Ambwani SR; Singh S
    Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical Use of Cannabinoids.
    Fraguas-Sánchez AI; Torres-Suárez AI
    Drugs; 2018 Nov; 78(16):1665-1703. PubMed ID: 30374797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
    Hwang J; Adamson C; Butler D; Janero DR; Makriyannis A; Bahr BA
    Life Sci; 2010 Apr; 86(15-16):615-23. PubMed ID: 19527737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cannabinoids and the expanded endocannabinoid system in neurological disorders.
    Cristino L; Bisogno T; Di Marzo V
    Nat Rev Neurol; 2020 Jan; 16(1):9-29. PubMed ID: 31831863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endocannabinoid system as an emerging target of pharmacotherapy.
    Pacher P; Bátkai S; Kunos G
    Pharmacol Rev; 2006 Sep; 58(3):389-462. PubMed ID: 16968947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocannabinoid System in Neurological Disorders.
    Ranieri R; Laezza C; Bifulco M; Marasco D; Malfitano AM
    Recent Pat CNS Drug Discov; 2016; 10(2):90-112. PubMed ID: 27364363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses.
    Bisogno T; Di Marzo V
    Curr Pharm Des; 2008; 14(23):2299-3305. PubMed ID: 18781980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.
    Estrada JA; Contreras I
    Curr Neuropharmacol; 2020; 18(8):769-787. PubMed ID: 32065105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabinoid drugs and enhancement of endocannabinoid responses: strategies for a wide array of disease states.
    Karanian DA; Bahr BA
    Curr Mol Med; 2006 Sep; 6(6):677-84. PubMed ID: 17022737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
    Aymerich MS; Aso E; Abellanas MA; Tolon RM; Ramos JA; Ferrer I; Romero J; Fernández-Ruiz J
    Biochem Pharmacol; 2018 Nov; 157():67-84. PubMed ID: 30121249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can Physical Activity Support the Endocannabinoid System in the Preventive and Therapeutic Approach to Neurological Disorders?
    Charytoniuk T; Zywno H; Konstantynowicz-Nowicka K; Berk K; Bzdega W; Chabowski A
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration.
    Basavarajappa BS; Nixon RA; Arancio O
    Mini Rev Med Chem; 2009 Apr; 9(4):448-62. PubMed ID: 19356123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of cannabinoids in schizophrenia.
    Kucerova J; Tabiova K; Drago F; Micale V
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):13-25. PubMed ID: 24605939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endocannabinoid system and multiple sclerosis.
    Baker D; Pryce G
    Curr Pharm Des; 2008; 14(23):2326-36. PubMed ID: 18781983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis.
    Jacobson MR; Watts JJ; Boileau I; Tong J; Mizrahi R
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):330-348. PubMed ID: 30635160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoids and endocannabinoids as therapeutics for nervous system disorders: preclinical models and clinical studies.
    Duncan RS; Riordan SM; Gernon MC; Koulen P
    Neural Regen Res; 2024 Apr; 19(4):788-799. PubMed ID: 37843213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.